IGSF1 (Immunoglobulin Superfamily 1) gene defects cause central hypothyroidism and macroorchidism. However, the pathogenic mechanisms of the disease remain unclear. Based on a patient with a full deletion of IGSF1 clinically followed from neonate to adulthood, we investigated a common pituitary origin for hypothyroidism and macroorchidism, and the role of IGSF1 as regulator of pituitary hormone secretion. The patient showed congenital central hypothyroidism with reduced TSH biopotency, over-secretion of FSH at neonatal minipuberty and macroorchidism from 3 years of age. His markedly elevated inhibin B was unable to inhibit FSH secretion, indicating a status of pituitary inhibin B resistance. We show here that IGSF1 is expressed both in thyrotropes and gonadotropes of the pituitary and in Leydig and germ cells in the testes, but at very low levels in Sertoli cells. Furthermore, IGSF1 stimulates transcription of the thyrotropin-releasing hormone receptor (TRHR) by negative modulation of the TGFβ1-Smad signaling pathway, and enhances the synthesis and biopotency of TSH, the hormone secreted by thyrotropes. By contrast, IGSF1 strongly down-regulates the activin-Smad pathway, leading to reduced expression of FSHB, the hormone secreted by gonadotropes. In conclusion, two relevant molecular mechanisms linked to central hypothyroidism and macroorchidism in IGSF1 deficiency are identified, revealing IGSF1 as an important regulator of TGFβ/Activin pathways in the pituitary.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338029 | PMC |
http://dx.doi.org/10.1038/srep42937 | DOI Listing |
Cureus
December 2024
Internal Medicine, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, PRT.
Autoimmune polyglandular syndromes (APS) are characterized by associations of two or more autoimmune diseases (AID). APS type 3 is characterized by the presence of autoimmune thyroid disease associated with other AID, excluding adrenal gland involvement. Here we report a case of a 64-year-old male, with history of type 1 diabetes mellitus (T1DM), diagnosed at the age of 32, who was referred to a Diabetes consultation in 2014 due to poor metabolic control.
View Article and Find Full Text PDFBMC Psychiatry
January 2025
Social Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Purpose: Depression and anxiety are the main disorders in patients suffering from hypothyroidism. These disorders can lead to increased patient suffering. Since hypothyroidism is one of the most prevalent endocrine diseases, controlling the metabolic variables that increase the severity of anxiety and depression is important.
View Article and Find Full Text PDFJ Gastrointest Cancer
January 2025
Ophir Loyola Hospital, Belém, Pará, 66063-240, Brazil.
Background And Objective: Gastric cancer (GC) remains a leading cause of morbidity and mortality worldwide. The current standard of care involves neoadjuvant chemotherapy (NACT) followed by radical gastrectomy. This study aims to evaluate the efficacy of neoadjuvant therapy with PD-1/PD-L1 inhibitors in comparison to chemotherapy alone for patients with locally advanced gastric cancer (LAGC).
View Article and Find Full Text PDFJ Neurosurg Case Lessons
January 2025
Department of Neurological Surgery, University of California, San Diego, La Jolla, California.
Background: Rathke cleft cysts (RCCs) are benign sellar/suprasellar lesions that result from mucin-secreting vestigial remnants within the pars intermedia of the pituitary gland. When symptomatic, they can present with retro-orbital headaches, visual field defects, and/or pituitary dysfunction.
Observations: A 35-year-old female presented with subacute retro-orbital headache, right ptosis, and blurred vision.
Endocr Connect
January 2025
K Kostev, Epidemiology, IQVIA, Frankfurt am Main, Germany.
Background: Thyroid dysfunctions, such as hypothyroidism, hyperthyroidism, are known to influence metabolism, but their long-term impact on the development of type 2 diabetes mellitus (T2D) in humans remains elusive. Thus, this study aimed to assess the cumulative incidence and association between thyroid disorders and T2D development.
Methods: We conducted a retrospective cohort study using data from the Disease Analyzer database (IQVIA™) from 2005 to 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!